FDA grants priority review to Vivitrol for opioid dependence (En)
VIVITROL (naltrexone) 380mg/vial for injection by Alkermes May 25, 2010. Alkermes announced that the supplemental New Drug Application (sNDA) for Vivitrol (naltrexone for extended-release injectable suspension) for opioid dependence has been granted priority review by the FDA. Priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status...
Διαβασε περισσότερα